Nitric oxide‐donating non‐steroidal anti‐inflammatory drugs are safer than traditional
NSAIDs and inhibit the growth of prostate cancer cells with greater potency than NSAIDs. In …

Hypoxic cancer cells are resistant to treatment, leading to the selection of cells with a more
malignant phenotype. The expression of interleukin-8 (IL-8) plays an important role in the …

Objectives The aim of this study was to investigate the effects of induction and knocking
down of hypoxia-inducible factor (HIF)-1α and/or-2α on tumor biology in androgen …

Objectives: Hypoxia is associated with human non-small cell lung cancers (NSCLC), which
are highly resistant to chemotherapy. The hypoxia inducible factor (HIF) as a transcription …

This study aimed to investigate the effects of knocking down hypoxia-inducible factor-1α (HIF-
1α) through RNA interference on hypoxia-induced increases in drug resistance in …

Our work aimed at identifying the antitumoral potential of new nitric oxide (NO)-releasing
non-steroidal anti-inflammatory drug (NSAID) derivatives on human prostate and bladder …

Purpose: To understand the role of hypoxia in prostate tumor progression and to evaluate
the ability of the novel unidirectional hypoxia-activated prodrug OCT1002 to enhance the …

Hypoxia induced drug resistance is a major obstacle in the development of effective cancer
therapy. Our previous study revealed that hypoxia‐inducible factor‐1 (HIF‐1), the major …

Prostate cancer (PCa) is one of the most common cancers in Western countries and
acquires a malignant phenotype, androgen-independent growth. PCa under hypoxia often …

Purpose: Hypoxia-inducible factors HIF-1α and HIF-2α are considered to be potential targets
for antineoplastic therapy because they regulate the expression of genes that contribute to …